THE ROLE OF HSA-MIR-451A IN THE GROWTH AND PROGRESSION OF LUMINAL BREAST CANCER
DOI:
https://doi.org/10.55766/sujst-2024-03-e02698Keywords:
Micrornas, Invasion, Migration, Cancer, Proliferation, hsa-miR-451aAbstract
Numerous genetic and biological processes have been linked to the function of microRNAs which regulate gene expression by targeting messenger RNA mRNA. MicroRNAs play a role in the development of disease and the embryology of mammals. To further understand its function in the oncogenic process, the expression of the microRNA profile in cancer has been investigated.
Despite being referred to as a noteworthy microRNA in cancer, it is unknown whether hsa-miR-451a plays a part in the in vitro progression of the luminal A and luminal B subtypes of breast cancer. Activity of hsa-miR-451a was examined when it was transfected and expressed in breast cancer cell lines known as luminal A and luminal B, in terms of the normal stages of cancer progression in vitro, such as proliferation, survival, migration, and invasion. We also thoroughly investigated target score-based bioinformatics algorithms for predicting microRNA-mRNA interactions. The progression (proliferation, migration, invasion) of luminal A and B breast cancer cell lines in vitro was markedly slowed by the expression of exogenous hsa-miR-451a. Based on bioinformatics analysis, we found a powerful interaction between hsa-miR-451a and the genes for CAB39, AKT1, and BRAF. In silico and experimental results confirmed a detailed gene network that boosts the activation of signaling pathways required for cancer progression and under expression of hsa-miR-451a it was decreased.
Absence of hsa-miR-451a in breast cancer tissue and its correlation with prognosis and tumor behavior provides a significant contribution that supports current contexts such as liquid biopsies and precision oncology based on bioinformatics tools and data mining.
References
Acheampong, T., Kehm, R.D., Terry, M.B., Argov, E.L., and Tehranifar, P. (2020). Incidence Trends of Breast Cancer Molecular Subtypes by Age and Race/Ethnicity in the US From 2010 to 2016. JAMA Network Open, 3(8):e2013226. https://doi.org/10.1001/jamanetworkopen.2020.13226
Ades, F., Zardavas, D., Bozovic-Spasojevic, I., Pugliano, L., Fumagalli, D., De Azambuja, E., Viale, G., Sotiriou, C., and Piccart, M. (2014). Luminal B breast cancer: Molecular characterization, clinical management, and future perspectives. Journal of Clinical Oncology, 32(25):2,794-2,803. https://doi.org/10.1200/JCO.2013.54.1870
Al-thoubaity, F.K. (2020). Molecular classification of breast cancer: A retrospective cohort study. Annals of Medicine and Surgery, 49:44-48. https://doi.org/10.1016/j.amsu.2019.11.021
Albert, V., Piendl, G., Yousseff, D., Lammert, H., Hummel, M., Ortmann, O., Jagla, W., Gaumann, A., Wege, A.K., and Brockhoff, G. (2022). Protein kinase C targeting of luminal (T-47D), luminal/HER2-positive (BT474), and triple negative (HCC1806) breast cancer cells in-vitro with AEB071 (Sotrastaurin) is efficient but mediated by subtype specific molecular effects. Archives of Gynecology and Obstetrics, 306:1,197-1,210. https://doi.org/10.1007/s00404-022-06434-2
Artemenko, M., Zhong, S.S.W., To, S.K.Y., and Wong, A.S.T. (2022). p70 S6 kinase as a therapeutic target in cancers : More than just an mTOR effector. Cancer Letters, 535:215593. https://doi.org/10.1016/j.canlet.2022.215593
Bediaga, N.G., Beristain, E., Calvo, B., Viguri, M.A., Gutierrez-Corres, B., Rezola, R., Ruiz-Diaz, I., Guerra, I., and de Pancorbo, M.M. (2016). Luminal B breast cancer subtype displays a dicotomic epigenetic pattern. SpringerPlus, 5:1-10. https://doi.org/10.1186/s40064-016-2235-0
Brix, N., Samaga, D., Belka, C., Zitzelsberger, H., and Lauber, K. (2021). Analysis of clonogenic growth in vitro. Nature Protocols, 16(11):4,963-4,991. https://doi.org/10.1038/s41596-021-00615-0
Chen, H.C. (2005). Boyden chamber assay. Cell Migration, 294:15-22. https://doi.org/10.1385/1-59259-860-9:015
Cho, J.H., Robinson, J.P., Arave, R.A., Burnett, W.J., Kircher, D. A., Chen, G., Davies, M.A., Grossmann, A.H., VanBrocklin, M.W., McMahon, M., and Holmen, S.L. (2015). AKT1 Activation Promotes Development of Melanoma Metastases. Cell Reports, 13(5):898-905. https://doi.org/10.1016/j.celrep.2015.09.057
Costanzo, V., Bardelli, A., Siena, S., and Abrignani, S. (2018). Exploring the links between cancer and placenta development. Open Biology, 8:1-11. https://doi.org/10.1098/rsob.180081
Creighton, C.J. (2012). The molecular profile of luminal B breast cancer. Biologics: Targets and Therapy, 6:289-297. https://doi.org/10.2147/BTT.S29923
Delicato, A., Montuori, E., Angrisano, T., Pollice, A., and Calabr, V. (2021). YB-1 Oncoprotein Controls PI3K / Akt Pathway by Reducing Pten Protein Level. Pubmed, 12(10):1551. https://doi.org/10.3390/genes12101551
Duronio, R.J. and Xiong, Y. (2013). Signaling pathways that control cell proliferation. Cold Spring Harbor Perspectives in Biology, 5(3): a008904 https://doi.org/10.1101/cshperspect.a008904
Evdokimova, V., Tognon, C., Ng, T., Sorensen, P.H.B., Evdokimova, V., Tognon, C., Ng, T., and Sorensen, P.H.B. (2009). Reduced proliferation and enhanced migration : mechanisms of metastatic progression by YB-1. Taylor and Francis, 8(18):2,901-2,906. https://doi.org/10.4161/cc.8.18.9537
Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., Liu, B., Lei, Y., Du, S., Vuppalapati, A., Luu, H.H., Haydon, R.C., He, T.C., and Ren, G. (2018). Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes and Diseases, 5(2):77–106. https://doi.org/10.1016/j.gendis.2018.05.001
García-Cortés, D., Hernández-Lemus, E., and Espinal-Enríquez, J. (2021). Luminal A Breast Cancer Co-expression Network: Structural and Functional Alterations. Frontiers in Genetics, 12:1-16. https://doi.org/10.3389/fgene.2021.629475
Goldhirsch, A., Winer, E.P., Coates, A.S., Gelber, R.D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.J., Albain, K.S., André, F., Bergh, J., Bonnefoi, H., Bretel-Morales, D., Burstein, H., Cardoso, F., Castiglione-Gertsch, M., Coates, A.S., Colleoni, M., Costa, A., Curigliano, G., Wood, W.C. (2013). Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013. Annals of Oncology, 24(9):2,206-2,223. https://doi.org/10.1093/annonc/mdt303
Grisham, R.N., Iyer, G., Garg, K., Delair, D., Hyman, D.M., Zhou, Q., Iasonos, A., Berger, M.F., Dao, F., Spriggs, D.R., Levine, D.A., Aghajanian, C., and Solit, D.B. (2013). BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. American Cancer Society Journals, 119(3):548-554. https://doi.org/10.1002/cncr.27782
Guo, H., Nan, Y., Zhen, Y., Zhang, Y., Guo, L., Yu, K., Huang, Q., and Zhong, Y. (2016). miRNA-451 inhibits glioma cell proliferation and invasion by downregulating glucose transporter 1. Tumor Biology, 37(10):13,751-13,761. https://doi.org/10.1007/s13277-016-5219-3
Guo, Y., Shang, X., and Li, Z. (2019). Identification of cancer subtypes by integrating multiple types of transcriptomics data with deep learning in breast cancer. Neurocomputing, 324:20-30. https://doi.org/10.1016/j.neucom.2018.03.072
Haling, J.R., Sudhamsu, J., Yen, I., Sideris, S., Sandoval, W., Phung, W., Bravo, B.J., Giannetti, A.M., Peck, A., Masselot, A., Morales, T., Smith, D., Brandhuber, B.J., Hymowitz, S.G., and Malek, S. (2014). Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling. Cancer Cell, 26(3):402-413. https://doi.org/10.1016/j.ccr.2014.07.007
Heron-Milhavet, L., Khouya, N., Fernandez, A., and Lamb, N.J. (2011). Akt1 and Akt2: Differentiating the action. Histology and Histopathology, 26(5):651-662.
Herschkowitz, J.I., He, X., Fan, C., and Perou, C.M. (2008). The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Research, 10(5):1-13. https://doi.org/10.1186/bcr2142
Hoeflich, K.P., Gray, D.C., Eby, M.T., Tien, J.Y., Wong, L., Bower, J., Gogineni, A., Zha, J., Cole, M.J., Stern, H.M., Murray, L.J., Davis, D.P., and Seshagiri, S. (2006). Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Research, 66(2):999-1006. https://doi.org/10.1158/0008-5472.CAN-05-2720
Holliday, D.L. and Speirs, V. (2011). Choosing correct breast cancer cell line for breast cancer research. Breast Cancer Research, 13(4):1-7. https://doi.org/10.1186/bcr2889
Huang, H.Y., Lin, Y.C.D., Li, J., Huang, K.Y., Shrestha, S., Hong, H.C., Tang, Y., Chen, Y.G., Jin, C.N., Yu, Y., Xu, J.T., Li, Y.M., Cai, X.X., Zhou, Z.Y., Chen, X.H., Pei, Y.Y., Hu, L., Su, J.J., Cui, S.D., and Huang, H.Da. (2020). miRTarBase 2020: Updates to the experimentally validated microRNA-target interaction database. Nucleic Acids Research, 48(D1):D148-D154. https://doi.org/10.1093/nar/gkz896
Hussain, M.R.M., Baig, M., Mohamoud, H.S.A., Ulhaq, Z., Hoessli, D.C., Khogeer, G.S., Al-Sayed, R.R., and Al-Aama, J.Y. (2015). BRAF gene: From human cancers to developmental syndromes. Saudi Journal of Biological Sciences, 22(4):359-373. https://doi.org/10.1016/j.sjbs.2014.10.002
Jain, K. and Basu, A. (2014). The multifunctional protein Kinase C-ε in cancer development and progression. Cancers, 6(2):860-878. https://doi.org/10.3390/cancers6020860
Kim, Y., and Kim, V.N. (2012). MicroRNA Factory: RISC Assembly from Precursor MicroRNAs. Molecular Cell, 46(4):384-386. https://doi.org/10.1016/j.molcel.2012.05.012
Klein, C.A. (2020). Cancer progression and the invisible phase of metastatic colonization. Nature Reviews Cancer, 20(11):681-694. https://doi.org/10.1038/s41568-020-00300-6
Liu, D., and Zhou, K. (2020). BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction. Clinical Breast Cancer, 20(1):41-50 https://doi.org/10.1016/j.clbc.2019.08.005
Pascut, D., Pratama, M.Y., Vo, N.V.T., Masadah, R., and Tiribelli, C. (2020). The crosstalk between tumor cells and the microenvironment in hepatocellular carcinoma: The role of exosomal micrornas and their clinical implications. Cancers, 12(4):1-20. https://doi.org/10.3390/cancers12040823
Peng, L., Yan, H., Qi, S., and Deng, L. (2020). Cab39 promotes the proliferation of nasopharyngeal carcinoma cne-1 cells via up-regulating p-jnk. Cancer Management and Research, 12:11,203-11,209. https://doi.org/10.2147/CMAR.S252476
Petri, B.J. and Klinge, C.M. (2020). Regulation of breast cancer metastasis signaling by miRNAs. Cancer and Metastasis Reviews, 39:837-886. https://doi.org/10.1007/s10555-020-09905-7
Porta, C., Paglino, C., and Mosca, A. (2014). Targeting PI3K/Akt/mTOR signaling in cancer. Frontiers, 4:1–11. https://doi.org/10.3389/fonc.2014.00064
Riggio, A.I., Varley, K.E., and Welm, A.L. (2021). The lingering mysteries of metastatic recurrence in breast cancer. British Journal of Cancer, 124(1):13-26. https://doi.org/10.1038/s41416-020-01161-4
Ross, C.A. (2015). The Trophoblast Model of Cancer. Taylor and Francis, 67(1):61-67. https://doi.org/10.1080/01635581.2014.956257
Ross, C.A. (2018). Future Research Directions for the Trophoblast Model of Cancer. Nutrition and Cancer, 70(5):755-760. https://doi.org/10.1080/01635581.2018.1470652
Sadria, M., Seo, D., and Layton, A.T. (2022). The mixed blessing of AMPK signaling in Cancer treatments. BMC Cancer, 1-16. https://doi.org/10.1186/s12885-022-09211-1
Sears, R. and Gray, J.W. (2018). Epigenomic Inactivation of RasGAPs Activates RAS Signaling in a Subset of Luminal B Breast Cancers. Cancer Discovery, 7(2):131-133. https://doi.org/10.1158/2159-8290.CD-16-1423
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., and Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3):209-249. https://doi.org/10.3322/caac.21660
Suzuki, H.I., Katsura, A., Matsuyama, H., and Miyazono, K. (2015). MicroRNA regulons in tumor microenvironment. Oncogene, 34(24):3,085-3,094. https://doi.org/10.1038/onc.2014.254
Tuasha, N. and Petros, B. (2020). Heterogeneity of tumors in breast cancer: Implications and prospects for prognosis and therapeutics. Scientifica, 2020(1):4736091. https://doi.org/10.1155/2020/4736091
Turajlic, S., Sottoriva, A., Graham, T., and Swanton, C. (2019). Resolving genetic heterogeneity in cancer. Nature Reviews Genetics, 20:404-416. https://doi.org/10.1038/s41576-019-0114-6
Vidal, D.O., Ramão, A., Pinheiro, D.G., Muys, B.R., Lorenzi, J. C.C., Alves, C.deP., Zanette, D.L., de Molfetta, G.A., Duarte, G., and Silva, W.A. (2018). Highly expressed placental miRNAs control key biological processes in human cancer cell lines. Oncotarget, 9:23,554-23,563. https://doi.org/10.18632/oncotarget.25264
Vlachos, I.S., Zagganas, K., Paraskevopoulou, M.D., Georgakilas, G., Karagkouni, D., Vergoulis, T., Dalamagas, T., and Hatzigeorgiou, A.G. (2015). DIANA-miRPath v3.0: Deciphering microRNA function with experimental support. Nucleic Acids Research, 43(W1), W460-W466. https://doi.org/10.1093/nar/gkv403
Wang, L., Zhang, S., and Wang, X. (2021). The Metabolic Mechanisms of Breast Cancer Metastasis. Frontiers in Oncology, 10:1-21. https://doi.org/10.3389/fonc.2020.602416
Zaman, A., Wu, W., and Bivona, T.G. (2019). Targeting oncogenic braf: Past, present, and future. Cancers, 11(8):1-19. https://doi.org/10.3390/cancers11081197
Zhu, X., Li, Y., Xu, G., and Fu, C.Q. (2020). Growth hormone receptor promotes breast cancer progression via the BRAF/MEK/ERK signaling pathway. FEBS Open Bio, 10(6):1,013-1,020. https://doi.org/10.1002/2211-5463.12816
